Imperium Health Medical Weight Loss | Melbourne, FL

Wegovy vs Ozempic vs Compounded Semaglutide: Key Differences Explained Wegovy vs Ozempic vs Compounded Semaglutide: Which Option Makes Sense? Patients exploring weight loss medications often ask early on: Wegovy vs Ozempic vs compounded semaglutide . While these treatments are closely related, they are not interchangeable , and the differences matter when it comes to access, dosing flexibility, cost, and long-term results . At Imperium Health, patients frequently raise this question. Understanding how each option is used helps guide informed, medically supported decisions , rather than relying solely on brand recognition or internet trends. Understanding the Shared Foundation All three options are built around the same active compound: semaglutide . This GLP-1 receptor agonist supports weight loss by reducing appetite, improving insulin sensitivity, and slowing gastric emptying. The distinctions begin with how the compound is delivered, regulated, and prescribed : Wegovy and Ozempic...

Screening Checklist: Are You a Good Candidate for Weight Loss Peptides? Peptide therapy and GLP-1 weight-loss injections can support fat loss, appetite control, and lean mass preservation when matched to the right person and carefully supervised. Use this practical screening checklist to decide whether you may be a good candidate, what to prepare before a consult, and which red flags mean you should choose a different path. This guide is designed for answer-engine friendliness, with clear sections, short lists, and direct takeaways you can act on today. Quick answer Good candidates have a clear fat-loss goal, stable medical conditions, and are ready to follow a protein-forward diet and resistance training plan. Not a fit when there is active cancer, unmanaged diabetes, untreated sleep apnea, pregnancy, or inability to commit to follow-ups. Baseline labs, medication review, and a slow, supervised start reduce side effects and improve results. Self-screening checklist Answer yes or no t...